Bernstein Interprets MRNA's 177% Surge: What Are the Fundamentals and What Is Speculation?

TL;DR
· The successful Phase III trial of INTerpath-001 validated that Moderna's mRNA platform can extend beyond respiratory vaccines, but complete efficacy data has yet to be disclosed.
· Moderna's single-day surge of 177% is difficult to explain solely by pipeline value; platform revaluation, short covering, and the 'cancer vaccine' narrative collectively amplified the market movement.
· Success in melanoma cannot be directly extrapolated to other indications like lung cancer and kidney cancer; cross-cancer replication remains key to realizing platform value.
· INT is essentially a personalized tumor therapy, and the custom production costs along with a 50/50 profit split may limit profit release.
· Clinical breakthroughs have occurred, but the efficacy across different cancers and commercialization efficiency remain unverified, and Moderna's performance inflection point is still unconfirmed.

On August 19, Moderna and Merck announced the Phase III topline results of the personalized neoantigen therapy intismeran autogene (referred to as INT) in combination with Keytruda for the treatment of high-risk melanoma.

The INTerpath-001 trial included 1,137 patients with stage IIB to IV cutaneous melanoma who had undergone surgical resection and had not received systemic treatment prior. The trial achieved both the primary endpoint of recurrence-free survival (RFS) and a key secondary endpoint of distant metastasis-free survival (DMFS) in its first interim analysis. Overall survival data is still immature, and the trial will continue.

The company has only confirmed that the results are statistically significant and clinically meaningful, without disclosing specific risk ratios, confidence intervals, patient subgroups, or complete safety data. In other words, the market has confirmed the trial's success but does not yet know how strong the efficacy is.

Following the announcement, Moderna's stock surged approximately 177% to $174.38, adding about $45 billion to its market capitalization; Merck rose about 13% to $152.20, increasing its market cap by about $50 billion. The market debate quickly shifted from 'Can the trial succeed?' to 'Can such a scale of increase be supported by fundamentals?'

Clinical Breakthroughs Are Real, But Not Enough to Explain the 177% Surge

Bernstein believes that the achievement of RFS and DMFS endpoints in the first interim analysis of INTerpath-001 suggests that the efficacy may be quite positive.

Interim analyses typically require crossing higher statistical thresholds. The report speculates that the RFS risk ratio for the Phase III trial may be between 0.50 and 0.65, and the DMFS risk ratio may be close to 0.40, roughly consistent with previous Phase II data.

A risk ratio below 1 indicates that the relative risk of recurrence, distant metastasis, or death events in the combination therapy group is lower than that in the Keytruda monotherapy group. For example, a risk ratio of 0.50 roughly represents a 50% reduction in the risk of related events, but does not mean half of the patients are cured.

The aforementioned range is merely Bernstein's speculation based on statistical thresholds and prior data, not the company's disclosed Phase III results. Specific efficacy, safety, and overall survival trends still need to await complete data.

However, the significance of this trial extends beyond melanoma. It is Moderna's first key trial to achieve success outside of respiratory vaccines and the first personalized neoantigen approach to demonstrate the potential to further improve Keytruda's efficacy in a Phase III study.

This provides critical clinical evidence for mRNA's expansion from infectious disease vaccines to tumor treatments and marks the starting point for the market to reassess Moderna's platform value.

The Market Trades on Platform Revaluation and Short Covering

Clinical results can explain the stock price increase, but not the magnitude of the rise.

Bernstein believes that even with the most optimistic success expectations for all later-stage projects of INT, it is difficult to support Moderna's approximately 177% single-day increase. This market movement is primarily driven by three overlapping forces:

1. Clinical success has reduced the residual risk of the melanoma project;
2. Investors are beginning to price in the platform potential of mRNA's expansion to more cancer types;
3. High short positions triggered short covering, amplifying short-term buying.

Before the results were announced, approximately 14% to 15% of Moderna's float was shorted. After the clinical results exceeded pessimistic expectations, shorts were forced to buy to cover, and previously underweight investors began to chase the stock. On that day, Moderna's trading volume approached 200 million shares, roughly equivalent to half of the company's total shares outstanding.

MRNA stock price chart (left) and short ratio chart (right). After the surge on August 19, 2026, MRNA's stock price returned to pre-pandemic levels, while approximately 14-15% of the float was shorted, creating conditions for a short squeeze. Clinical data triggered the rise, but short covering further amplified the increase.

The news label of 'cancer vaccine success' further reinforced the propagation effect. Compared to 'personalized neoantigen therapy achieving endpoints in Phase III,' this phrasing more easily leads the market to associate with a large platform covering multiple cancer types.

Thus, clinical data is the trigger for the increase, while platform narrative, short covering, and news effects amplified the rise. The amount by which the stock price increased does not mean the market has confirmed that INT can generate equivalent revenue and profit.

Melanoma Is Just the Starting Point; Platform Replication Still Needs Verification

Moderna and Merck are currently laying out four Phase III studies and five Phase II studies around INT, covering melanoma, non-small cell lung cancer, renal cell carcinoma, and bladder cancer, and have begun to enter unresectable or metastatic tumors.

Bernstein estimates that the potential patient population corresponding to INTerpath-001 in the U.S. is about 13,000 to 19,000, accounting for approximately 30% of the reachable patient population for Phase III and potential registrational Phase II projects, and about 17% of all Phase II and III projects.

The potential patient population corresponding to INTerpath-001 in the U.S. is estimated to be about 13,000 to 19,000, accounting for only about 30% of the total reachable patient population for current key projects and about 17% of all II and III INT studies. Success in melanoma does not mean that lung cancer, kidney cancer, and other cancer types can automatically replicate the same results.

If projects like lung cancer, kidney cancer, and bladder cancer can also replicate the success of melanoma, the market space for INT will significantly expand. Bernstein currently provides an unadjusted sales forecast of approximately $2.4 billion for early-stage melanoma and lung cancer.

The report also uses Keytruda as an upward reference: its revenue from early cancer indications is expected to be approximately $7.9 billion in 2025 and about $9.2 billion in 2028, while INT's future pricing may exceed that of Keytruda.

However, $2.4 billion is an unadjusted sales forecast, not profit, and certainly not realized performance. INT has yet to cover several important indications for Keytruda, including triple-negative breast cancer, cervical cancer, and head and neck cancer.

More critically, melanoma typically has strong immunogenicity, and its success cannot be directly extrapolated to tumors with different immune environments, such as lung cancer, kidney cancer, and bladder cancer.

INTerpath-001 has demonstrated the potential for the platform to replicate, but it has not proven that replication will definitely occur. The market has begun to trade on the success of other cancer types, but relevant clinical data is still forthcoming.

Therefore, Bernstein maintains a 'Market Perform' rating for Moderna and a target price of $45, significantly lower than the closing price of $174.38 on August 19.

The 'Cancer Vaccine' Label Obscures Commercial Reality

INT is not a preventive vaccine aimed at healthy populations, but a personalized treatment for cancer patients. At this stage, it is used for adjuvant therapy after patients have completed tumor resection, aiming to reduce the risk of recurrence and distant metastasis from residual lesions.

Each patient must have tumor tissue and blood samples collected individually, followed by genetic sequencing and algorithm analysis. The system screens up to 34 specific neoantigens from the patient's tumor mutations and then produces corresponding mRNA constructs to induce T-cell responses against the tumor.

Thus, while INT utilizes Moderna's mRNA platform, its business model is closer to personalized tumor drugs:

• Target patients are in the tens of thousands, rather than the tens of millions or hundreds of millions typical of traditional vaccines;
• Each patient requires individual sequencing, design, and production;
• Production costs are difficult to dilute quickly like mass vaccines;
• Regulation, pricing, and reimbursement will also follow the path of tumor drugs.

The 'cancer vaccine' label is an easily disseminated term, but it may amplify the market's imagination about patient scale while downplaying the real constraints of individualized production costs and commercialization efficiency. The incremental impact of INT's success on traditional vaccine raw material suppliers is also relatively limited.

How Much Profit Can Be Left from Billion-Dollar Revenue?

Bernstein is more concerned about INT's profit margins than the sales potential.

Merck will be responsible for global commercialization, while Moderna will participate in joint promotion in the U.S., and Merck will independently handle marketing and sales in markets outside the U.S. Both parties will share costs and profits as per their agreement.

Using melanoma as a single indication example, Bernstein assumes that INT's peak sales will reach $1.2 billion, with gross margins gradually increasing from 35% at launch to 60%. After deducting approximately $250 million in sales and administrative expenses and sharing profits, the mature stage's contribution to Moderna's earnings per share is about $0.6.

This is Bernstein's scenario calculation, not the company's guidance. It illustrates that even if INT becomes a billion-dollar product, individualized production costs and profit sharing will still limit profit release.

However, the current market pricing already implies multiple favorable conditions: the successful expansion to other cancer types, smooth expansion of custom production, pricing and reimbursement landing, and continuous improvement in gross margins. None of these conditions have been fully verified yet.

For Merck, the strategic value of INT mainly lies in expanding the use of Keytruda. Most trials are designed to compare 'INT in combination with Keytruda' against 'Keytruda alone,' making INT primarily an adjunct therapy rather than a replacement for Keytruda.

If the combination regimen becomes the new standard of care, Bristol Myers Squibb's Opdivo, Roche's Tecentriq, and AstraZeneca's Imfinzi may face market share pressure in parts of the melanoma and non-small cell lung cancer markets. However, lower initial gross margins and profit sharing may also drag down INT's contribution to Merck's operating profit margins.

Thus, Merck's market cap increase of about $50 billion is also difficult to explain solely by the current melanoma project's profits.

The Rise in the Pharmaceutical Sector Also Reflects AI Trading Rotation

Bernstein believes that this market movement is not entirely a story about Moderna's individual stock.

The report observes that recent trading in the pharmaceutical and semiconductor sectors has shown certain reverse trading characteristics. In the context of increasing concentration in AI and semiconductor holdings, pharmaceuticals have begun to be viewed by some investors as a relatively clean defensive choice: demand is less affected by economic cycles and may benefit in the long term from AI's application in drug development and clinical trials.

In 2026, the pharmaceutical sector (DRG) and semiconductor index (SOX) exhibited significant reverse trading characteristics. When AI themes fluctuate and funds flow out of tech stocks, the pharmaceutical sector receives inflows as a defensive asset. Moderna's rise is not just an individual stock story but also a result of sector rotation.

This is merely Bernstein's explanation of funding behavior and does not imply a stable negative correlation between pharmaceuticals and semiconductors. However, when tech stocks experience increased volatility, funding rotation may provide additional buying pressure for the pharmaceutical sector, amplifying the market impact of INT's clinical results.

Thus, Moderna's rise encompasses three layers of trading: the underlying layer is the success of melanoma in Phase III, the middle layer is the revaluation of the mRNA platform, and the outer layer is short covering and sector rotation. The further out you go, the more the market movement distances itself from quantifiable fundamentals.

From Clinical Breakthroughs to Performance Inflection Points, Three Verifications Are Still Needed

INTerpath-001 has already proven that mRNA personalized neoantigen therapy can achieve success in a large Phase III trial. However, to define it as Moderna's performance inflection point, at least three verifications are still needed:

1. Complete Phase III data. Specific risk ratios, safety, patient subgroups, and overall survival trends will determine INT's real advantage relative to Keytruda monotherapy.
2. Cross-cancer replication. Subsequent results from lung cancer, kidney cancer, and bladder cancer will determine whether melanoma is just a favorable indication or the starting point for a broader tumor platform.
3. Commercialization efficiency. Custom production cycles, capacity, pricing, reimbursement, and gross margins will determine whether sales can convert into profits sufficient to support valuations.

Bernstein does not deny the clinical value of INTerpath-001. His real warning is that the market has rapidly jumped from a successful melanoma trial to pricing the endgame of a multi-cancer platform and long-term profit realization.

Clinical breakthroughs have occurred, but the performance inflection point has yet to be confirmed. The current stock price reflects more of the imagination of platform success and the short-term demand amplified by high short positions.